About Passage Bio
Passage Bio is a company based in Philadelphia (United States) founded in 2017 by Stephen Squinto. Passage Bio has raised $225.5 million across 3 funding rounds from investors including New Leaf Venture Partners, Orbimed and Frazier Healthcare Partners. The company has 60 employees as of December 31, 2024. Passage Bio operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Philadelphia, United States
- Employees 60 as on 31 Dec, 2024
- Founders Stephen Squinto
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Passage Bio, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$64.77 M (USD)36.54as on Dec 31, 2024
-
EBITDA
-$62.09 M (USD)35.61as on Dec 31, 2024
-
Total Equity Funding
$225.5 M (USD)
in 3 rounds
-
Latest Funding Round
$50 M (USD), Post-IPO
Sep 09, 2021
-
Investors
New Leaf Venture Partners
& 10 more
-
Employee Count
60
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Passage Bio
Passage Bio is a publicly listed company on the NASDAQ with ticker symbol PASG in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Passage Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Passage Bio
Passage Bio has successfully raised a total of $225.5M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Passage Bio
Passage Bio has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include New Leaf Venture Partners, Orbimed and Frazier Healthcare Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Healthcare sector private equity investments are managed by the firm.
|
Locked | Locked | Locked |
Investor details for Passage Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Passage Bio
Investment portfolio details for Passage Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Passage Bio
Detailed financials for Passage Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Passage Bio Comparisons
Peer comparison for Passage Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Passage Bio
Passage Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of Passage Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Passage Bio
Complete news archive for Passage Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Passage Bio
Passage Bio was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Passage Bio is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
William Chou is the current CEO of Passage Bio.
Passage Bio is a funded company, having raised a total of $225.5M across 3 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Passage Bio is 60.
Passage Bio was founded in 2017 in Philadelphia, United States, within the biotechnology sector. AAV-delivered therapeutics are developed for rare monogenic central nervous system diseases. Lead programs are directed toward GM1 gangliosidosis, frontotemporal dementia, and Krabbe disease. Operations center on advancing gene therapy solutions for these conditions, with research and development conducted in the U.S. geographic area.
Passage Bio's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Yes, Passage Bio is publicly traded on NASDAQ under the ticker symbol PASG.
Passage Bio has 11 investors. Key investors include New Leaf Venture Partners, Orbimed, Frazier Healthcare Partners, Versant Ventures, and Lilly Asia Ventures.
The ticker symbol of Passage Bio is PASG on NASDAQ.